SEC Tracker
Get the app

Spero Therapeutics SPRO

Spero Therapeutics: reports quarterly results, announces exit or restructuring costs and 2 other items

Form
8-K
Filed
Period
Importance
Major
Document
8-K
Exhibit 99.1
Press release
  • Reports quarterly results (2.02)
  • Announces exit or restructuring costs (2.05)
  • Makes a Regulation FD disclosure (7.01)
  • Discloses other events (8.01)

Not explained yet; the original is on EDGAR.

View on EDGAR

Open in the app

Get an email when Spero Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Lineage Cell Therapeutics LCTX public float $162M, Jun 30, 2025
  2. Forte Biosciences FBRX public float $157M, Jun 30, 2025
  3. Monopar Therapeutics MNPR public float $156M, Jun 30, 2025
  4. 4D Molecular Therapeutics FDMT public float $166M, Jun 30, 2025
  5. XOMA Royalty XOMA public float $168M, Jun 30, 2025